Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
5 Horizons Capital is a venture capital organization founded in 2022 and headquartered in Oklahoma City, USA. The firm specializes in supporting clinical-stage biotechnology companies through a unique Venture Capital-as-a-Service (VCaaS) model. This model combines capital investment with advisory services and partnerships with Contract Research Organizations (CROs), facilitating the clinical development process for biotech companies. By aligning incentives and focusing on capital efficiency, 5 Horizons aims to streamline the journey from discovery to clinical trials.
As of now, 5 Horizons Capital operates primarily in the seed, seed-plus, and Series A stages, with a focus on early-stage clinical biotechnology companies. The firm has established a notable portfolio that includes companies such as Piston Bio, Higher Medicine, and Kadence Bio. Their approach emphasizes thorough diligence across scientific, clinical, operational, and financial aspects, ensuring that investments are strategically aligned with CRO milestones and trial progression.
5 Horizons Capital has also formed strategic partnerships with organizations like Novotech, enhancing their operational capabilities and providing additional resources to their portfolio companies. This partnership model is designed to support clinical-stage biotechs in navigating the complexities of clinical trials more effectively.
5 Horizons Capital focuses on investing in clinical-stage biotechnology companies, particularly those at the Series A stage. Their investment strategy emphasizes capital efficiency and aligned incentives among stakeholders. The firm conducts comprehensive diligence across scientific, clinical, operational, and financial aspects to ensure that investments are strategically aligned with milestones set by CROs and the progression of clinical trials.
The firm’s unique VCaaS model integrates capital investment with advisory services and partnerships with CROs, which enhances the operational capabilities of their portfolio companies. This approach not only provides financial support but also facilitates the clinical development process, allowing startups to navigate the complexities of clinical trials more effectively. 5 Horizons Capital seeks to partner with founders who demonstrate a strong commitment to advancing their clinical-stage biotechs and who align with the firm’s focus on capital efficiency.
5 Horizons Capital has collaborated with several notable biotech companies, including:
This portfolio reflects 5 Horizons Capital's commitment to supporting clinical-stage biotechs through strategic investments and operational support.
Aaron Ray — Partner & Co-Founder. Aaron has over 20 years of experience in private equity, venture capital, business development, and consulting. His expertise spans various sectors, particularly in biotechnology.
Bill — Partner & Co-Founder. Bill has over 30 years of experience in investment banking, capital markets, M&A, and the medical device industry. His extensive background supports the firm's strategic investment approach.
Walter Hong, MD — Founder and CEO of Piston Bio. Walter brings a wealth of knowledge in clinical development and biotechnology.
Leo Kim, Ph.D. — Founder and CEO of Higher Medicine. Leo has a strong background in clinical research and operational execution in the biotech sector.
John Boghossian — CEO of Kadence Bio. John has significant experience in leading biotech companies through clinical trials and operational challenges.
To pitch to 5 Horizons Capital, founders should visit their website at 5 Horizons Capital. The pitch deck should include comprehensive details about the startup's scientific and clinical progress, operational strategies, and financial projections. Founders are encouraged to highlight how their company aligns with CRO milestones and the potential for capital efficiency.
Response times may vary, but founders can expect to hear back regarding their submissions. Warm introductions are beneficial but not strictly necessary.
In September 2025, 5 Horizons Capital participated in a $28M Series A funding round for LPOXY Therapeutics, aimed at supporting the STOP-Cdiff Pivotal Trial. This investment highlights the firm's commitment to advancing clinical-stage biotechs through strategic funding.
Additionally, 5 Horizons Capital has been actively involved in supporting its portfolio companies, including providing operational support and comprehensive evaluations. Their strategic investments have been recognized in various press releases, showcasing their role in the biotech sector.
What are the investment criteria for 5 Horizons Capital?
5 Horizons Capital primarily invests in early-stage clinical biotechnology companies, focusing on those in the Series A stage. The firm emphasizes thorough diligence across scientific, clinical, operational, and financial aspects to ensure alignment with CRO milestones and trial progression.
How can founders pitch to 5 Horizons Capital?
Founders can submit their pitch through the official website at 5 Horizons Capital. It is recommended to include detailed information about the company's scientific and clinical progress, operational plans, and financial projections.
What makes 5 Horizons Capital different from other VC firms?
The firm operates under a unique Venture Capital-as-a-Service (VCaaS) model, integrating capital investment with advisory services and partnerships with CROs. This model enhances operational capabilities and supports clinical-stage biotechs in navigating the complexities of clinical trials.
What is the geographic focus of 5 Horizons Capital?
5 Horizons Capital primarily invests in companies based in the United States, with a specific focus on the biotech and healthcare sectors.
What is the typical check size for investments?
While specific check sizes are not disclosed, the firm focuses on seed, seed-plus, and Series A investments, indicating a range that aligns with early-stage funding needs.
What kind of post-investment support does 5 Horizons Capital provide?
5 Horizons Capital adds value through operational execution and strategic partnerships with CROs, helping portfolio companies navigate clinical trials and enhance their operational capabilities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.